Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Condition: Non-hodgkin Lymphoma Interventions: Drug: Methotrexate; Drug: Rituximab (where available); Drug: Ibrutinib Sponsors: Canadian Cancer Trials Group; Janssen Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials